Cyclacel Pharmaceuticals, Inc. (CYCC) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Selling, general and administrative: 1.27M
Today's EPS Names:
PKE, BYRN, HELE, More
Financial Fact:
Selling, general and administrative: 1.27M
Today's EPS Names:
PKE, BYRN, HELE, More
Join SI Premium – FREE
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q2 EPS of ($0.22), $0.08 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $264 thousand, versus $356 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare sinks on Medicare rating changes
- Concentra to Announce Third Quarter 2026 Results on Thursday, November 5, 2026
- Enterprise Declares Quarterly Distribution
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
